Blood-based biomarkers for the optimization of anti-angiogenic therapies

about

Blood-based biomarkers for the optimization of anti-angiogenic therapies

Item

http://www.wikidata.org/entity/Q37328390

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Blood-based biomarkers for the optimization of anti-angiogenic therapies

@en

Blood-based biomarkers for the optimization of anti-angiogenic therapies.

@nl

type

Item

label

Blood-based biomarkers for the optimization of anti-angiogenic therapies

@en

Blood-based biomarkers for the optimization of anti-angiogenic therapies.

@nl

prefLabel

Blood-based biomarkers for the optimization of anti-angiogenic therapies

@en

Blood-based biomarkers for the optimization of anti-angiogenic therapies.

@nl

P1476

Blood-based biomarkers for the optimization of anti-angiogenic therapies

@en

P2093

Cristina Rabascio

http://www.w3.org/2001/XMLSchema#string

P2860

Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability

Tumor angiogenesis

Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

P304

1027-1039

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/CANCERS2021027

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Bertolini

P577

2010-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258954916

http://www.w3.org/2001/XMLSchema#string

P698

24281105

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

3835117

http://www.w3.org/2001/XMLSchema#string